You are here > The Company  > Management



Executive Management

John Tchelingerian, PhD,
Chief Executive Officer

Etienne Sokal, MD, PhD,
Chief Innovation and Scientific Officer

Frank Hazevoets,
Chief Financial Officer & Head of Corporate Development

Torsten Hombeck, PhD,
Chief Commercial and Strategy Officer

Patrick Stragier,
Vice President Operations


Board of Directors

Pr. Dr. Christof Hettich,
Chairman of the Board (representing Hopp Family)

Director: John Tchelingerian, PhD
(CEO and Series A Director)

Director: Alain Parthoens
(representing Vesalius BioCapital)

Director: Dr Ilka Wicke
(representing Boehringer Ingelheim Venture Fund)

Director: Kinji Fuchikami
(representing Mitsui & Co Global Investments)

Director: Philippe Degive
(representing SRIW)

Director: Pr Etienne Sokal
(Founder and Series A Director)

Director: Dr Jean-Paul Prieels
(representing SFPI)

Observer: Ingo Koesfeld
(representing SMS-Investments)

Observer: Charlie Alexander
(representing Shire)



Mustapha Najimi,
Scientific Advisor



John Tchelingerian,PhD: Chief Executive Officer                         


Dr John Tchelingerian is a serial entrepreneur and a private investor. His background includes strong scientific, business, managerial and deal making experience. He has co-founded and managed several biotech companies including Neurotech, Key-Obs and Diatos. In the past ten years he has raised over $100 million (€ 81 million) for his entrepreneurial ventures from VCs and private equity sources in Europe, the US and Japan. He has also closed several biotech and pharma partnering deals. Under his leadership four drugs were developed from the research stage up to clinical phase IIb/III and a marketed drug, DaunoXome, was re-launched in a cancer orphan indication both in the USA and the EU, based on phase III clinical trials.

John co-founded a strategic advisory and corporate finance firm Silver Ocean Ventures in 2009; based in Paris. It primarily services the global life sciences industry regarding corporate finance, strategic business transactions and active board and leadership roles. Under his leadership Silver Ocean Ventures has closed several international capital raising and M&A transactions. As a scientist, John has invented several patents in the field of cell therapy and drug delivery.

He is a PhD graduate in Neurosciences from Pierre et Marie Curie University in Paris, France. He is fluent in five languages.  


 Back to top


Professor Etienne Sokal, MD, PhD: Chief Innovation and Scientific Officer

Etienne Sokal

Pr Etienne Sokal is a medical entrepreneur and innovation driven; he founded Promethera on February 12th  2009,  with the UCL Technology Transfer Office (Sopartec-LTTO). 

He is CSO & CIO of Promethera Biosciences and member of the board.

He is a paediatric hepatologist with 30 years experience in the fields of  liver diseases and liver transplantation. He is head of the Paediatric gastroenterology and hepatology service at Cliniques Universitaires St Luc (Brussels, Belgium) and full professor at Université Catholique de Louvain (UCL) (Belgium). More than 1000 children from many different countries have received liver transplantation at St Luc, and many others have been treated  for  various  acquired or congenital liver diseases, including liver based metabolic disorders.   

Prof E Sokal is heading the UCL lab of pediatric hepatology and cell therapy laboratory (Institute of Experimental and Clinical Research); he discovered Hepastem in 2005 and obtained   several additional  patents in the filed of stem cells. 

More than 300 peer-reviewed publications (Scopus h index 55)  demonstrate the level of excellence of the team, which is internationally recognized.  The recent breakthrough in liver stem cell technology has also positioned the team within the leaders.


Back to top


Frank Hazevoets, Chief Financial Officer & Head Corporate Development

Frank Hazevoets

Frank Hazevoets is a highly experienced senior financial executive with over twenty-five years international business experience. He trained at the Catholic University of Leuven (KUL) in Belgium as a commercial engineer and also obtained a master degree in Artificial Intelligence and Cognitive Science. He has worked in leading positions in corporate finance and investment banking (Puilaetco, BACOB/Smeets Securities, BBL/ING), strategy and business development (InBev). During his six years as CFO at Tigenix, he supported the company in its funding and growth strategy and helped them to obtain the first European marketing authorization for cell-based medicinal products in Europe.


Back to top


Torsten Hombeck, PhD, Chief Commercial & Strategy Officer / MD Promethera LLC

Torsten Hombeck

MBA and PhD in Finance from the European Business School, Germany<br\> Executive in the life science industry with over 15 years of U.S. and European experience in public and private biopharmaceutical companies.<br\> Former Co-CEO and CBO of Cytonet, Co-CEO and CFO of Agennix, CFO of GPC Biotech


Back to top


Patrick Stragier: Vice President Operations

Patrick Stragier is the Vice Persident of Operations, in charge of Manufacturing and Quality Control at Promethera Biosciences.

Biochemist with more than 25 years of international operational and managerial experience, he has worked for biopharmaceutical companies such as Solvay, DSM-Biologics, Genzyme and Lonza.

Since 2009, he has been working as a consultant specialized in cell therapy. He is the co-founder of MaSTherCell. Patrick Stragier joined Promethera Biosciences in September 2015.


Back to top


Mustapha NajimiScientific adviser and member of the scientific board: Mustapha Najimi, PhD

Mustapha Najimi is a senior researcher at at the Experimental and Clinical Research Institute of the Université catholique de Louvain (UCL) (Belgium). He was a member of the founding team of Promethera Biosciences and is co-owner of 2 patents on HHALPC.

He earned his doctoral degree (Cell & Molecular Biology) in 1999 at the Université Pierre & Marie Curie in Paris. Dr Najimi is currently leading the Stem cells’ group and Cell culture platform at the Pediatric Hepatology & Cell Therapy laboratory (UCL, Belgium). Dr Najimi is the scientific supervisor of the hepatocytes and hepatic stem cells banks at Saint-Luc Hospital (Brussels, Belgium).

His main research interest is focused on hepatic stem cells biology and liver regeneration. He is invited reviewer for several journals of Hepatology and Cell Therapy fields.


Back to top



PROMETHERA Biosciences S.A./N.V.
Watson & Crick Hill
Rue Granbonpré, 11
B-1435 Mont-Saint-Guibert
Tél.: +32 (0)10 39 43 00
Fax: +32 (0)10 39 43 01

News and Public release

CEO John Tchelingerian to Discuss Strategic Collobarations and Partnering Strategies in Cell Therapy at ARM’s Advanced Therapies Summit
Collaboration to Drive Development and Commercialization of Promethera’s Cell-based Liver-Focused Therapeutics Portfolio in Korea